Phase 2 Hearing Loss Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People of any age may be considered, depending on which group (cohort) within the trial they are being assessed for
- People who have at least two changes (mutations) in a specific gene called the otoferlin gene
- People who have been assessed and found to have severe hearing loss in both ears, caused by a problem with the inner ear or hearing nerve (confirmed through a specialised hearing test called an ABR)
- People whose inner ear still shows some preserved function on a specific type of hearing test called a DPOAE test
- People who are able and willing to follow all study requirements, including taking part in a separate long-term follow-up study after this trial ends
Who may not be able to join:
- People who have ongoing ear infections, unusual ear anatomy, or other health conditions that would make surgery, anaesthesia, or receiving an experimental gene therapy unsafe
- People who already have a cochlear implant in the ear that would be treated in this trial
- People who have taken part in a study involving an experimental drug within the six months before treatment, or who have ever previously taken part in any gene therapy clinical trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Peter Marks, MD, Eli Lilly and Company
Phone: +1 857-410-1816
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Frequency of Adverse Events (AEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.